– FRANCE, Vélizy-Villacoublay – Novacyt (EPA: ALNOV | LON: NCYT), a leading international specialist in clinical diagnostics, today announced the appointment of David Allmond to its Board of Directors as CEO effective from 18 October 2021, succeeding Graham Mullis who will retire as CEO and board member.
“The Board is highly confident that, after an extensive search, we have found the right leader for Novacyt’s next chapter of growth, following Graham’s decision to retire. We look forward to working with David and the recently strengthened senior management team to deliver on the Company’s strategy of organic, R&D and acquisitive growth that we recently reiterated at our full year results.” said Board Chairman, James Wakefield.
About David Allmond
David Allmond brings relevant leadership experience in life science companies experiencing significant development and growth and developing businesses into new global markets. Currently, he is CBO at Amryt Pharma (Nasdaq: AMYT | AIM: AMYT), where he has played a key role in developing the company into a leading global rare and orphan disease drug company. Earlier in his career, David held sales and marketing roles of increasing seniority at Amgen, Celgene, and Aegerion Pharmaceuticals. David received a BSc in microbiology from Imperial College. David will be supported by Novacyt’s recently strengthened executive management team.
David Allmond, CEO-elect of Novacyt, said: “I am excited to be joining Novacyt at a pivotal phase in its development and I am looking forward to building upon Graham’s outstanding work with the business over the past 13 years. Novacyt is poised for its next phase of growth and I am confident I can lead the Company effectively through this period, working closely with the excellent management team and Board to make a significant contribution to global health and deliver sustained and ongoing value to our shareholders.”
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialization, contract design, and manufacturing. The Company’s lead business units comprise Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, hematology, and serology markets as do its global partners, which include major corporates.
For more information: https://novacyt.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.